1436 - Real-World Treatment Utilization Patterns, Discontinuation and Healthcare Resource Utilization of First-Line (1L) Bruton Tyrosine Kinase Inhibitor (BTKi) Therapy in Chronic Lymphocytic Leukemia (CLL): Age-Related Disparity

Primary Author / Presenter(s)

SC

Swetha Challagulla, MS

BeOne Medicines Ltd
San Carlos, California, United States
PC

Po-Ya Chuang, MBA

Real Chemistry
New York, New York, United States
WF

Wesley Furnback, BS

Real Chemistry
New York, New York, United States
Sikander Ailawadhi, MD

Professor of Medicine; Lead, International Cancer Center
Department of Cancer Biology, Mayo Clinic
Jacksonville, Florida, United States